New triple therapy aims to boost immune attack on tough cancers
NCT ID NCT04495257
First seen Nov 01, 2025 · Last updated May 12, 2026 · Updated 22 times
Summary
This early-phase study tests whether adding an experimental drug (APX005M) to two standard immunotherapies is safe and tolerable for people with advanced melanoma or kidney cancer. About 26 adults who have not had prior immune therapy for their advanced disease will receive the combination. The main goals are to find the best dose and to monitor side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Yale Cancer Center
New Haven, Connecticut, 06519, United States
-
Yale New Haven Hospital
New Haven, Connecticut, 06520, United States
Conditions
Explore the condition pages connected to this study.